logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

NPM1-mutated AML: reduced relapses with gemtuzumab ozogamicin added to induction, first consolidation

Reduced incidence of relapse in those achieving CR/CRi.